AR010361A1 - "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS" - Google Patents

"S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"

Info

Publication number
AR010361A1
AR010361A1 ARP970105920A ARP970105920A AR010361A1 AR 010361 A1 AR010361 A1 AR 010361A1 AR P970105920 A ARP970105920 A AR P970105920A AR P970105920 A ARP970105920 A AR P970105920A AR 010361 A1 AR010361 A1 AR 010361A1
Authority
AR
Argentina
Prior art keywords
metoxi
omeprazole
manufacture
pharmaceutical composition
preparation
Prior art date
Application number
ARP970105920A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR010361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR010361A1 publication Critical patent/AR010361A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

S-omeprazol (S-5-metoxi-2-[[(4-mmetoxi-3,5-dimetil-2-piridinil)-metil] sulfinil]-1H-bencimidazol) en una forma neutral que se caracteriza porque seencuentra en estado parcialmente cristalino o en estado sustancialmente cristalino, talco mo en la Forma A o en la Forma B, procesos para supreparacion, composicion farmacéutica, su uso para la manufactura de medicamentos y método de tratamiento. El compuesto 5-metoxi-2-[[(4-metoxi-3,5-dimetil-2-piridinil)-metil]sulfinil]-1H-be ncimidazol, teniendo el nombre genérico de omeprazol, y las sales terapéuticamente aceptables del mismo, seencuentran descriptas en la PE 5129. Las sales alcalinas específicas de omeprazol se encuentran reveladas en la PE 124495. El o meprazol es efectivocomo inhibidor en la secrecion del ácido gástrico y es util como agente antiulcera. En sentido más general, se puede utilizar el omeprazol para laprevencion y el tratamiento de enfermedades relacionadas con elácido gástri co en los mamíferos, y especialmente en el hombre.
ARP970105920A 1996-12-20 1997-12-16 "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS" AR010361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer

Publications (1)

Publication Number Publication Date
AR010361A1 true AR010361A1 (es) 2000-06-07

Family

ID=20405146

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105920A AR010361A1 (es) 1996-12-20 1997-12-16 "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"

Country Status (37)

Country Link
US (1) US6162816A (es)
EP (1) EP0946547B1 (es)
JP (1) JP4402174B2 (es)
KR (1) KR20000069595A (es)
CN (1) CN1109684C (es)
AR (1) AR010361A1 (es)
AT (1) ATE236898T1 (es)
AU (1) AU730129B2 (es)
BR (1) BR9714059A (es)
CA (1) CA2274076C (es)
CZ (1) CZ294784B6 (es)
DE (1) DE69720774T2 (es)
DK (1) DK0946547T3 (es)
EE (1) EE03923B1 (es)
EG (1) EG24414A (es)
ES (1) ES2194231T3 (es)
HK (1) HK1022909A1 (es)
HU (1) HU227589B1 (es)
ID (1) ID21850A (es)
IL (1) IL130450A0 (es)
IS (1) IS1981B (es)
MY (1) MY117032A (es)
NO (1) NO317191B1 (es)
NZ (1) NZ336024A (es)
PL (1) PL190377B1 (es)
PT (1) PT946547E (es)
RS (1) RS49685B (es)
RU (1) RU2184734C2 (es)
SA (1) SA97180739B1 (es)
SE (1) SE510666C2 (es)
SI (1) SI0946547T1 (es)
SK (1) SK285151B6 (es)
TR (1) TR199901410T2 (es)
TW (1) TW538039B (es)
UA (1) UA55436C2 (es)
WO (1) WO1998028294A1 (es)
ZA (1) ZA9711046B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
SE9804003D0 (sv) * 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
JP2000344739A (ja) * 1999-06-01 2000-12-12 Sumitomo Chem Co Ltd Ｎ−保護−アゼチジン−２−カルボン酸の製造方法
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
ES2511774T3 (es) 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
CA2775616C (en) 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
WO2002098352A2 (en) 2001-06-01 2002-12-12 Pozen Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
GB2376231A (en) 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
WO2004002982A2 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
DE60311809T2 (de) * 2002-06-27 2007-11-22 Dr. Reddy's Laboratories Ltd. Verfahren zur herstellung optisch reiner oder optisch angereicherter sulfoxidverbindungen einschliesslich amorphen esomeprazols und dessen salze
WO2004020436A1 (en) * 2002-08-30 2004-03-11 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
EA200500673A1 (ru) * 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
CN1777598A (zh) * 2003-02-28 2006-05-24 兰贝克赛实验室有限公司 S－奥美拉唑的多晶型物
CN100364987C (zh) * 2003-03-24 2008-01-30 卫材R&D管理有限公司 亚砜衍生物或其盐的非定形态的制备方法
CN1842525A (zh) * 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
WO2006001753A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1885711A1 (en) * 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
EP1907375B1 (en) * 2005-06-08 2013-07-24 LEK Pharmaceuticals d.d. Crystalline solvate of omeprazole sodium
WO2006134605A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
NL2000126C2 (nl) * 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
WO2007054951A1 (en) * 2005-11-14 2007-05-18 Hetero Drugs Limited Process for amorphous esomeprazole
AU2006323245B2 (en) * 2005-12-05 2011-03-03 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7799925B2 (en) 2005-12-28 2010-09-21 Unión Químico Farmacéutica, S.A. Process for the preparation of the (S)-enantiomer of omeprazole
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
US8106210B2 (en) 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
JP2011513202A (ja) 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
CA2736547C (en) * 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
SI2510089T1 (sl) 2009-12-08 2015-12-31 Codexis, Inc. Sinteza prazolnih spojin
HUE037616T2 (hu) 2010-12-08 2018-09-28 Codexis Inc Biokatalizátorok és eljárások armodafinil szintéziséhez
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
RU2501549C1 (ru) 2012-08-30 2013-12-20 Авва Девелопмент Лтд Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни
CN107043367A (zh) * 2017-05-26 2017-08-15 重庆莱美隆宇药业有限公司 一种中性s‑奥美拉唑的干燥工艺
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
EP0723436B1 (en) * 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i

Also Published As

Publication number Publication date
MY117032A (en) 2004-04-30
DE69720774T2 (de) 2004-02-05
SA97180739B1 (ar) 2006-05-20
EP0946547A1 (en) 1999-10-06
WO1998028294A1 (en) 1998-07-02
SK285151B6 (sk) 2006-07-07
HUP0001547A3 (en) 2002-06-28
HUP0001547A2 (hu) 2002-05-29
IS1981B (is) 2005-01-14
HK1022909A1 (en) 2000-08-25
RU2184734C2 (ru) 2002-07-10
JP2001507025A (ja) 2001-05-29
CZ294784B6 (cs) 2005-03-16
ID21850A (id) 1999-08-05
YU28199A (sh) 2002-03-18
EE9900259A (et) 2000-02-15
HU227589B1 (en) 2011-09-28
PT946547E (pt) 2003-07-31
RS49685B (sr) 2007-11-15
TW538039B (en) 2003-06-21
BR9714059A (pt) 2000-05-09
DK0946547T3 (da) 2003-06-30
CZ220299A3 (cs) 2000-02-16
NZ336024A (en) 2001-02-23
CA2274076C (en) 2008-09-30
PL334297A1 (en) 2000-02-14
NO317191B1 (no) 2004-09-13
ZA9711046B (en) 1998-06-22
SE9604793D0 (sv) 1996-12-20
US6162816A (en) 2000-12-19
NO993068D0 (no) 1999-06-21
KR20000069595A (ko) 2000-11-25
CA2274076A1 (en) 1998-07-02
EP0946547B1 (en) 2003-04-09
CN1109684C (zh) 2003-05-28
SE9604793L (sv) 1998-06-21
ES2194231T3 (es) 2003-11-16
EG24414A (en) 2009-05-25
ATE236898T1 (de) 2003-04-15
JP4402174B2 (ja) 2010-01-20
EE03923B1 (et) 2002-12-16
IL130450A0 (en) 2000-06-01
NO993068L (no) 1999-06-21
SE510666C2 (sv) 1999-06-14
TR199901410T2 (xx) 1999-08-23
AU730129B2 (en) 2001-02-22
UA55436C2 (uk) 2003-04-15
HU0001547D0 (es) 2002-05-29
DE69720774D1 (de) 2003-05-15
PL190377B1 (pl) 2005-12-30
SI0946547T1 (en) 2003-10-31
SK76599A3 (en) 1999-12-10
IS5070A (is) 1999-06-07
CN1241183A (zh) 2000-01-12
AU5502698A (en) 1998-07-17

Similar Documents

Publication Publication Date Title
AR010361A1 (es) "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"
CL2009000805A1 (es) Composicion farmaceutica que comprende a una sal sodica del enantiomero (-) de 5-metoxi-2[[(4-metoxi-3,5-dimetil-2-piridinil)metil]sulfinil]-1h-bencimidazol ((-)-omeprazol); y su uso en la inhibicion de la secrecion de acido gastrico y para tratar enfermedades inflamatorias gastrointestinales. (divisional solicitud 3570-00).
BR9816067A (pt) Forma a de omeprazol, omeprazol, processo para a preparação da forma a de omeprazol, formulação farmacêutica, uso de omeprazol, e, método de tratamento de distúrbios gastrointestinais.
LV10577A (lv) Omeprazola ka antimikrobu lidzekla lietosana
AR079473A2 (es) Compuesto cristalino de benzimidazol composicion farmaceutica que lo comprende y metodo para la manufactura de dicha composicion
ES2195345T3 (es) Nueva forma de s-omeprazol.
AR013350A1 (es) Sal de sodio de omeprazol forma b, proceso para su preparacion, formulacion farmaceutica, y uso de dicha sal para la fabricacion de medicamentos.
CO4750654A1 (es) Proceso para la sintesis de un compuesto omeprazol
BR9508292A (pt) Processos para a sintese enãncio-seletiva de um composto,(-)-5-metóxi-2[[(4-metóxi-3,5-dimetil-2-piridinil) metil]sulfinil]-1h-benzimidazol,(+)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h-benzimidazol,(+)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h benzimidazol composto e uso dos compostos
ATE346063T1 (de) Kristalline form von omeprazol
ATE110379T1 (de) Therapeutisch aktive substituierte benzimidazole und verfahren zu ihrer herstellung.
YU31199A (sh) Novi postupak
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
SE0302382D0 (sv) New salts II
JP2005523298A (ja) 非心臓性胸痛の治療のためのプロトンポンプ阻害剤の使用
US20050131026A1 (en) Use of proton pump inhibitors for the treatment of airway disorders
WO2005025569A1 (en) Use of known active ingredients as radical scavengers

Legal Events

Date Code Title Description
FG Grant, registration